Free Trial

Atea Pharmaceuticals (AVIR) SEC Filings & 10K Form

Atea Pharmaceuticals logo
$2.98 -0.01 (-0.33%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$2.98 0.00 (0.00%)
As of 05/2/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Atea Pharmaceuticals SEC Filings

DateFilerForm TypeView
04/29/2025
4:00 PM
Atea Pharmaceuticals (Filer)
Form DEF 14A
04/23/2025
7:14 PM
Atea Pharmaceuticals (Subject)
BlackRock, Inc. (Filed by)
Form SCHEDULE 13G/A
04/17/2025
11:23 AM
Atea Pharmaceuticals (Subject)
Radoff Bradley Louis (Filed by)
Form SCHEDULE 13D/A
04/17/2025
7:06 AM
Atea Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/03/2025
3:50 PM
Atea Pharmaceuticals (Filer)
Form DEFA14A
04/01/2025
8:21 AM
Atea Pharmaceuticals (Filer)
Form DEFA14A
04/01/2025
8:19 AM
Atea Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/26/2025
4:15 PM
Atea Pharmaceuticals (Filer)
Form DEFA14A
03/26/2025
1:30 PM
Atea Pharmaceuticals (Subject)
Radoff Bradley Louis (Filed by)
Form DFAN14A
03/24/2025
5:16 AM
Atea Pharmaceuticals (Filer)
Form DEFA14A
03/24/2025
5:10 AM
Atea Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/21/2025
10:58 AM
Atea Pharmaceuticals (Subject)
Radoff Bradley Louis (Filed by)
Form SCHEDULE 13D/A
03/06/2025
3:45 PM
Atea Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/04/2025
8:27 AM
Atea Pharmaceuticals (Subject)
Radoff Bradley Louis (Filed by)
Form SCHEDULE 13D
02/24/2025
5:52 PM
Atea Pharmaceuticals (Issuer)
Kirsch Arthur S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2025
5:47 PM
Atea Pharmaceuticals (Issuer)
Kirsch Arthur S (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
02/24/2025
7:17 AM
Atea Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/14/2025
11:47 AM
Atea Pharmaceuticals (Subject)
EcoR1 Capital, LLC (Filed by)
Form SCHEDULE 13G/A
02/04/2025
5:00 PM
Atea Pharmaceuticals (Issuer)
Foster Wayne (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/04/2025
5:00 PM
Atea Pharmaceuticals (Issuer)
Sommadossi Jean-Pierre (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/04/2025
5:00 PM
Atea Pharmaceuticals (Issuer)
Corcoran Andrea (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/04/2025
5:00 PM
Atea Pharmaceuticals (Issuer)
Horga Maria Arantxa (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/04/2025
5:00 PM
Atea Pharmaceuticals (Issuer)
Vavricka John (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/04/2025
5:00 PM
Atea Pharmaceuticals (Issuer)
Hammond Janet MJ (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2025
1:30 PM
Atea Pharmaceuticals (Issuer)
BERGER FRANKLIN M (Reporting)
Form 4/A
01/17/2025
7:03 AM
Atea Pharmaceuticals (Issuer)
BERGER FRANKLIN M (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2024
8:50 AM
Atea Pharmaceuticals (Subject)
BML Investment Partners, L.P. (Filed by)
Form SCHEDULE 13D
12/12/2024
5:00 PM
Atea Pharmaceuticals (Issuer)
BERGER FRANKLIN M (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/10/2024
4:17 PM
Atea Pharmaceuticals (Subject)
BERGER FRANKLIN M (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/19/2024
11:15 PM
Atea Pharmaceuticals (Filer)
Form EFFECT
11/15/2024
9:34 AM
Atea Pharmaceuticals (Subject)
EcoR1 Capital, LLC (Filed by)
Form SC 13G/A
11/07/2024
3:58 PM
Atea Pharmaceuticals (Filer)
Form S-3
Registration statement under Securities Act of 1933  
11/07/2024
3:41 PM
Atea Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/07/2024
3:27 PM
Atea Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/19/2024
7:02 PM
Atea Pharmaceuticals (Issuer)
Sommadossi Jean-Pierre (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/19/2024
3:22 PM
Atea Pharmaceuticals (Subject)
JPM Partners LLC (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/18/2024
3:09 PM
Atea Pharmaceuticals (Subject)
JPM Partners LLC (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/17/2024
3:16 PM
Atea Pharmaceuticals (Subject)
JPM Partners LLC (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/07/2024
3:45 PM
Atea Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/07/2024
3:15 PM
Atea Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/21/2024
4:59 PM
Atea Pharmaceuticals (Issuer)
Polsky Bruce (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
Musk's warning signal: Prepare before the cascade begins (Ad)

When Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t. With 40+ years of market modeling, he says Musk’s move wasn’t about efficiency — it was a signal. And what’s coming next could divide the market into winners and losers faster than anyone expects. Watch this urgent video briefing now.

Watch the Musk market warning before the dominoes fall
06/21/2024
5:00 PM
Atea Pharmaceuticals (Issuer)
Lucidi Bruno (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2024
5:06 PM
Adams Jerome M. (Reporting)
Atea Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2024
5:08 PM
Atea Pharmaceuticals (Issuer)
BERGER FRANKLIN M (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2024
5:12 PM
Atea Pharmaceuticals (Issuer)
Duncan Barbara Gayle (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2024
4:54 PM
Atea Pharmaceuticals (Issuer)
Murphy Polly A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2024
4:21 PM
Atea Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/20/2024
4:32 PM
Atea Pharmaceuticals (Subject)
Polsky Bruce (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/07/2024
5:34 PM
Atea Pharmaceuticals (Issuer)
Sommadossi Jean-Pierre (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2024
3:15 PM
Atea Pharmaceuticals (Filer)
Form DEFA14A
05/14/2024
3:43 PM
Atea Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/14/2024
3:16 PM
Atea Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:AVIR) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners